Asphyxia Associated Metabolite Biomarker Investigation (AAMBI)

Life Science Inkubator155 enrolled

Overview

Verification of biomarkers in a human population for their ability to diagnose the severity of neonatal asphyxia. These biomarkers linked to asphyxia have been identified in animal studies.

The aim of the study is to verify the application of combinations of several laboratory parameters in early postnatal blood samples, for identification of infants, who will suffer from early abnormal neonatal neurological outcome, in a population at risk. The population at risk is defined as term and late preterm (\>36 weeks of gestation) human infants following perinatal hypoxia-ischemia with or without postnatal resuscitation.

Study Type

OBSERVATIONAL

Enrollment

155

Conditions

Asphyxia Neonatorum

Interventions

blood samplingOTHER

small volume blood sampling, according to local laws, is not categorized as intervention (observational study)

Eligibility

Sex: ALLMin age: 0 HoursMax age: 2 HoursHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Group 1: inclusion criteria fulfilled for hypothermia treatment Group 2: Infants with suspected perinatal brain injury due to one of the followings * Perinatal hypoxia-ischemia (defined as a perinatal acidosis indicated by a pH≤7.10 or a base excess ≤-12mmol/l in umbilical cord blood or early postnatal blood collected at \<90min of age (outborn patients) * 5min APGAR-score ≤ 5 * Need for resuscitation after birth for \>1 min. after birth, positive pressure respiratory support with face mask or endotracheal tube, or cardiac compressions Group 3: UApH \>7,25, and adaptation disorder of the newborn and need of postnatal clinical surveillance Exclusion Criteria: gestational age \< 36 weeks * age at time of screening \>2,5h * congenital malformation * missing or invalid informed parental consent * unsuccessful resuscitation * infant considered not-viable * decision for palliative care only

Locations (4)

Cukurova University

Adana, Turkey (Türkiye)

University of Firat

Elâzığ, Turkey (Türkiye)

Özel Güngören Hastanesi

Istanbul, Turkey (Türkiye)

Mersin University School of Medicine

Mersin, Turkey (Türkiye)

Outcomes

Primary Outcomes

abnormal short-term outcome (NE)

All patients are classified as abnormal short-term outcome (neonatal encephalopathy, NE) or normal short term outcome (no encephalopathy) by using clinical data, particularly Thompson score. For Group 1 and group 2 patients outcome classification will be additionally confirmed by using cranial ultrasound or MRI (including severe ischemia based on DWI or thalamic or cerebellar bleeding or arterial infarction or IVH\>2° according to Papile, thalamic ischemia or severe cerebral edema) or seizure activity or burst suppression on aEEG or persistingly abnormal aEEG background pattern after complete rewarming. Bloodplasma samples will be analysed by a metabolomics approach using the p180-kit (Biocrates, Innsbruck, Austria). Metabolite concentrations or combinations thereof will be compared to the outcome described above in order to identify the most suitable metabolites to be used for early detection of NE in newborn infants.

Time frame: 14 days for clinical diagnosis

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.